Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib vs Pertuzumab in Neoadjuvant Treatment of Early/Locally Advanced HER2+ Breast Cancer
NCT07335081Phase 2Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Shanghai Jiao Tong University School of Medicine. Started Feb 2024; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07335081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07335081.